Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Nematode levamisole-sensitive nicotinic acetylcholine receptor 1 (L-AChR1) is a heteropentameric, ligand-gated ion channel essential for neuromuscular coordination in parasitic nematodes (Boulin et al., 2011). It belongs to the Cys-loop superfamily of receptors and is typically composed of subunits such as UNC-38, UNC-63, UNC-29, and ACR-8, though the exact composition can vary between species (Boulin et al., 2011; Williamson et al., 2009). Located at the neuromuscular junction, L-AChR1 mediates excitatory signals from motor neurons to body wall muscles; its activation by acetylcholine triggers cation influx, leading to muscle depolarization and contraction (MSD Veterinary Manual). This receptor is a primary target for several classes of anthelmintic drugs, including imidazothiazoles like levamisole and tetrahydropyrimidines like pyrantel, which act as potent agonists (Boulin et al., 2011; Martin et al., 2004). These drugs cause prolonged channel opening, leading to persistent depolarization and spastic paralysis, which results in the parasite's detachment and expulsion from the host (MSD Veterinary Manual). However, the widespread use of these anthelmintics has led to the emergence of resistance, often characterized by genetic polymorphisms or altered expression of the receptor's constituent subunits (Neveu et al., 2010).
Agonists (e.g., levamisole, pyrantel) induce persistent opening of the ligand-gated ion channel, leading to muscle depolarization, calcium influx, and spastic paralysis (Boulin et al., 2011; MSD Veterinary Manual). Antagonists (e.g., derquantel) block the receptor, preventing activation and leading to flaccid paralysis (Robertson et al., 2002).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nematode levamisole-sensitive nicotinic acetylcholine receptor 1 (L-AChR1).